CILIATECH
The purpose of the ciliatech is the research, development, production, exploitation, acquisition and distribution of pharmaceutical and diagnostic products and technologies. The Company may acquire, hold and dispose of any intellectual property rights or licenses of any kind. The Company may enter into any commercial, contractual or financial dealings that are likely to promote the Company's purpose or that are directly or indirectly related to it. It may also set up branch offices in Germany and abroad and participate in or partner with other companies.
CILIATECH
Industry:
Biotechnology Health Diagnostics Pharmaceutical
Founded:
2011-01-01
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.ciliatech.com
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Apache GoDaddy DNS GoDaddy GoDaddy Email Starfield Technologies
Official Site Inspections
http://www.ciliatech.com
- Host name: redirect.ovh.net
- IP address: 213.186.33.5
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "Ciliatech" on Search Engine
CILIATECH - CILIO-SCLERAL INTER-POSITIONING DEVICE
Discover CID (Cilio-Scleral Inter-positioning Device), the first implant to effectively reduce IntraOcular Pressure (IOP) without penetrating the anterior chamber or creating subconjunctival filtration – critical measures that overcome the most serious complications and shortcomings of other glaucoma surgical techniques.See details»
CILIATECH - Glaucoma Innovators | LinkedIn
CILIATECH is a medtech company specialized in ophthalmology, developing a new class of implant to address the increasing need to treat glaucoma durably and with almost zero adverse effects.See details»
Ciliatech - Crunchbase Company Profile & Funding
Ciliatech is a medtech company specialized in ophthalmology, develops a new class of implant to address the increasing need to treat glaucoma durably and with very minimal adverse effects.See details»
New glaucoma treatment development: the cilioscleral technique
Aug 9, 2023 New glaucoma treatment development: the cilioscleral technique. At the World Glaucoma Congress (WGC) in Rome, Italy this summer, Ciliatech presented preliminary results of the second 2-year postoperative clinical trial (SAFARI â…¡) on its Cilioscleral Interposition Device (CID).See details»
Ciliatech presents data on first-generation implant at World …
Jul 3, 2023 Ciliatech described CID as a groundbreaking device disrupting traditional approaches in glaucoma surgery. It is the first implant that enables surgeons to prolong reduced IOP while bypassing the anterior of the eye and sparing the conjunctiva.See details»
Ciliatech raises $3.87M in series A funding to develop new
May 1, 2023 Ciliatech SAS secured $3.87 million in series A funding to continue developing its second-generation implant to treat open-angle glaucoma. This round was led by its historical shareholders, including BNP Development SAS, Kreaxi SAS and individual investor Bernard Chauvin.See details»
Ciliatech Company Profile 2024: Valuation, Funding & Investors
Information on valuation, funding, cap tables, investors, and executives for Ciliatech. Use the PitchBook Platform to explore the full profile.See details»
Ciliatech releases new design of Cilioscleral Interpositioning …
Dec 11, 2023 Ciliatech, an ophthalmology medtech company developing a new implant to treat glaucoma durably, has released a new design of its CID (Cilioscleral Interpositioning Device), following the filing of additional patents strengthening its IP (Intellectual Property).See details»
Ciliatech presents groundbreaking concept in glaucoma implants, …
Sep 13, 2022 Ciliatech presents groundbreaking concept in glaucoma implants, first to bypass opening anterior eye chamber. Interim results of 12-month follow-up study on new implant that significantly reduces Intraocular pressure, while leaving anterior chamber untouched, will be presented at three events in Milan, Italy: Ophthalmology futures …See details»
Ciliatech releases new design of glaucoma surgical device CID ...
Dec 5, 2023 Ciliatech, a medtech company specialized in ophthalmology, is developing a new class of implant to address the increasing need to treat glaucoma durably and with zero adverse effects. Glaucoma affects 80M people per year worldwide.See details»
Ciliatech Releases New Design for Glaucoma Surgical Device
Dec 6, 2023 Ciliatech, an ophthalmology medtech company developing a new class of implant to treat glaucoma durably, released a new design of its CID (Cilioscleral Interpositioning Device), following the filing of additional patents strengthening its IP (Intellectual Property).See details»
Ciliatech Presents New Concept in Glaucoma Implants, First
Sep 13, 2022 Ciliatech, which is developing a new class of implant to treat glaucoma durably named CID (Cilio-scleral Inter-positioning Device), announced that the interim results of a 12-month follow-up study on its CID concept show strong potential to mark a new era in glaucoma surgery, according to a company news release.See details»
Ciliatech presents groundbreaking concept in glaucoma implants …
Ciliatech, a medtech company specialized in ophthalmology, is developing a new class of implant to address the increasing need to treat glaucoma durably and with zero adverse effects.See details»
Ciliatech presents groundbreaking concept in glaucoma implants, …
Sep 13, 2022 Ciliatech, a medtech company specialized in ophthalmology, is developing a new class of implant to address the increasing need to treat glaucoma durably and with zero adverse effects.See details»
Ciliatech Presents 2-Year Postoperative Results on New Cilio …
Jun 28, 2023 Ciliatech will present results showing stable IOP over time, within a safe zone average of 15 mmHg, among its second cohort of patients with primary open-angle glaucoma (POAG) who underwent a new cilio-scleral surgical procedure.See details»
Ciliatech Releases New Design of Glaucoma Surgical Device CID
Dec 5, 2023 CID is the unique glaucoma surgical device used in the cilioscleral technique to lower IOP while preserving the anterior chamber of the eye, which in turn avoids serious medical complications, notably endothelial cell loss (ECL) or a filtration bleb.See details»
Scientific Resources - Ciliatech
Jun 28, 2023 Ciliatech releases new design of glaucoma surgical device CID, following patent reinforcement. Second-generation CID (Cilioscleral Interpositioning Device) makes cilioscleral surgical procedure, which leaves anterior chamber of eye untouched, less invasive and easier to perform. See more. News.See details»
Ciliatech | VentureRadar
Ciliatech is a medtech company specialized in ophthalmology that is developing a new class of implant to address the need to treat glaucoma durably and with zero adverse effects.See details»
Ciliatech - Funding, Financials, Valuation & Investors - Crunchbase
Ciliatech is a medtech company specialized in ophthalmology.See details»
Two-year post-operative results on new cilio-scleral surgical …
Jun 28, 2023 Ciliatech will present results showing stable intraocular pressure (IOP) over time, within a safe zone average of 15 mmHg, among its second cohort of patients with Primary Open-Angle Glaucoma (POAG) who underwent a new …See details»